JP2015504421A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015504421A5 JP2015504421A5 JP2014540196A JP2014540196A JP2015504421A5 JP 2015504421 A5 JP2015504421 A5 JP 2015504421A5 JP 2014540196 A JP2014540196 A JP 2014540196A JP 2014540196 A JP2014540196 A JP 2014540196A JP 2015504421 A5 JP2015504421 A5 JP 2015504421A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- binding
- acid sequence
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 24
- 102000004965 antibodies Human genes 0.000 claims 21
- 108090001123 antibodies Proteins 0.000 claims 21
- 239000000427 antigen Substances 0.000 claims 15
- 102000038129 antigens Human genes 0.000 claims 15
- 108091007172 antigens Proteins 0.000 claims 15
- 241000589516 Pseudomonas Species 0.000 claims 12
- 238000006467 substitution reaction Methods 0.000 claims 6
- 102000018358 Immunoglobulins Human genes 0.000 claims 5
- 108060003951 Immunoglobulins Proteins 0.000 claims 5
- 229920000023 polynucleotide Polymers 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 206010061471 Pseudomonas infection Diseases 0.000 claims 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 claims 1
- 241001135917 Vitellaria paradoxa Species 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 108091006028 chimera Proteins 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 102000005614 monoclonal antibodies Human genes 0.000 claims 1
- 108010045030 monoclonal antibodies Proteins 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
Claims (18)
- シュードモナス属(Pseudomonas)PcrVに特異的に結合する単離結合分子またはその抗原結合断片であって、結合分子が:
(a)配列番号216のアミノ酸配列を含む重鎖可変領域(VH)および配列番号217のアミノ酸配列を含む軽鎖可変領域(VL)を含む抗体またはその抗原結合断片と同一のシュードモナス属(Pseudomonas)PcrVエピトープに特異的に結合する;
(b)配列番号216のアミノ酸配列を含む重鎖可変領域(VH)および配列番号217のアミノ酸配列を含む軽鎖可変領域(VL)を含む抗体またはその抗原結合断片によるシュードモナス属(Pseudomonas)PcrVへの結合を競合阻害する;または
(c)(a)および(b)の組み合わせ、
である、単離結合分子またはその抗原結合断片。 - 請求項1に記載の単離結合分子またはその抗原結合断片であって、以下:
(a)SYAMN(配列番号218)を含む重鎖CDR1、または1、2、3、もしくは4つの保存アミノ酸置換を含むそのバリアント;AITISGITAYYTDSVKG(配列番号219)を含む重鎖CDR2、または1、2、3、もしくは4つの保存アミノ酸置換を含むそのバリアント;およびEEFLPGTHYYYGMDV(配列番号220)を含む重鎖CDR3、または1、2、3、もしくは4つの保存アミノ酸置換を含むそのバリアント;
(b)RASQGIRNDLG(配列番号221)を含む軽鎖CDR1、または1、2、3、もしくは4つの保存アミノ酸置換を含むそのバリアント;SASTLQS(配列番号222)を含む軽鎖CDR2、または1、2、3、もしくは4つの保存アミノ酸置換を含むそのバリアント;ならびにLQDYNYPWT(配列番号223)を含む軽鎖CDR3、または1、2、3、もしくは4つの保存アミノ酸置換を含むそのバリアント;または
(c)(a)および(b)の組み合わせ、
を含む、単離結合分子またはその抗原結合断片。 - 請求項1に記載の単離結合分子またはその抗原結合断片であって、以下:
(a)配列番号216に対して少なくとも90%の配列同一性を有する重鎖可変領域;
(b)配列番号217に対して少なくとも90%の配列同一性を有する軽鎖可変領域;または
(c)(a)および(b)の組み合わせ、
を含む、単離結合分子またはその抗原結合断片。 - 抗体またはその抗原結合断片を含む、請求項1に記載の単離結合分子またはその抗原結合断片。
- 組換え抗体、モノクローナル抗体、キメラ抗体、ヒト化抗体、完全ヒト抗体、二重特異性抗体、またはそれらのいかなる組み合わせである、請求項4に記載の単離結合分子またはその抗原結合断片。
- (a)配列番号216を含む重鎖可変領域;および
(b)配列番号217を含む軽鎖可変領域
を含む、請求項5に記載の結合分子またはその断片。 - シュードモナス属(Pseudomonas)Pslに結合する結合ドメイン、およびシュードモナス属(Pseudomonas)PcrVに結合する結合ドメインを含む二重特異性抗体。
- (a)Psl結合ドメインが、scFv断片を含み、PcrV結合ドメインが、インタクトな免疫グロブリンを含む、または、
(b)Psl結合ドメインが、インタクトな免疫グロブリンを含み、PcrV結合ドメインが、scFv断片を含む、
請求項7に記載の二重特異性抗体。 - (a)scFvが、インタクトな免疫グロブリンのVH領域のアミノ末端に融合される;
(b)scFvが、インタクトな免疫グロブリンのCH3領域のカルボキシ末端に融合される;または
(c)scFvが、インタクトな免疫グロブリンのヒンジ領域に挿入される、
請求項8に記載の二重特異性抗体。 - 抗Psl結合ドメインが:
(a)配列番号11のアミノ酸配列を含むVHおよび配列番号12のアミノ酸配列を含むVLを含む抗体またはその抗原結合断片と同一のシュードモナス属(Pseudomonas)Pslエピトープに結合する;
(b)配列番号11のアミノ酸配列を含む重鎖可変領域(VH)および配列番号12のアミノ酸配列を含む軽鎖可変領域(VL)を含む抗体またはその抗原結合断片によるシュードモナス属(Pseudomonas)Pslへの結合を競合阻害できる;または
(c)(a)および(b)の組み合わせ、
である、請求項7に記載の二重特異性抗体。 - 抗PcrV結合ドメインが:
(a)配列番号216のアミノ酸配列を含むVHおよび配列番号217のアミノ酸配列を含むVLを含む抗体またはその抗原結合断片と同一のシュードモナス属(Pseudomonas)PcrVエピトープに結合する;
(b)配列番号216のアミノ酸配列を含むVHおよび配列番号217のアミノ酸配列を含むVLを含む抗体またはその抗原結合断片によるシュードモナス属(Pseudomonas)PcrVへの結合を競合阻止できる;または
(c)(a)および(b)の組み合わせ、
である、請求項7に記載の二重特異性抗体。 - 抗PcrV結合ドメインが、配列番号216のアミノ酸配列を含むVHおよび配列番号217のアミノ酸配列を含むVLを含む、請求項11に記載の二重特異性抗体。
- 抗Psl結合ドメインが、配列番号11のアミノ酸配列を含むVHおよび配列番号12のアミノ酸配列を含むVLを含み、抗PcrV結合ドメインが、配列番号216のアミノ酸配列を含むVHおよび配列番号217のアミノ酸配列を含むVLを含む、請求項7に記載の二重特異性抗体。
- 請求項1に記載の結合分子またはその断片、または請求項7に記載の二重特異性抗体またはその断片をコードするポリヌクレオチドを含む単離ポリヌクレオチド分子。
- 請求項1に記載の結合分子またはその断片、または請求項7に記載の二重特異性抗体またはその断片、および薬学的に許容可能な担体を含む組成物。
- シュードモナス属(Pseudomonas)Pslに結合する結合ドメインと、シュードモナス属(Pseudomonas)PcrVに結合する結合ドメインを含む、請求項15に記載の組成物。
- シュードモナス属(Pseudomonas)感染を予防または治療するための、請求項15に記載の組成物。
- 請求項15に記載の組成物を含むキット。
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161556645P | 2011-11-07 | 2011-11-07 | |
US61/556,645 | 2011-11-07 | ||
US201261625299P | 2012-04-17 | 2012-04-17 | |
US61/625,299 | 2012-04-17 | ||
US201261697585P | 2012-09-06 | 2012-09-06 | |
US61/697,585 | 2012-09-06 | ||
PCT/US2012/063722 WO2013070615A1 (en) | 2011-11-07 | 2012-11-06 | Combination therapies using anti- pseudomonas psl and pcrv binding molecules |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2015504421A JP2015504421A (ja) | 2015-02-12 |
JP2015504421A5 true JP2015504421A5 (ja) | 2015-12-24 |
JP6182152B2 JP6182152B2 (ja) | 2017-08-16 |
Family
ID=48290482
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014540196A Active JP6182152B2 (ja) | 2011-11-07 | 2012-11-06 | 抗シュードモナス属(Pseudomonas)PslおよびPcrV結合分子を用いた併用治療 |
Country Status (22)
Country | Link |
---|---|
US (3) | US10597439B2 (ja) |
EP (1) | EP2776065B1 (ja) |
JP (1) | JP6182152B2 (ja) |
KR (1) | KR102184343B1 (ja) |
CN (1) | CN104136042B (ja) |
AU (3) | AU2012336028A1 (ja) |
BR (1) | BR112014011028B1 (ja) |
CA (2) | CA2854817C (ja) |
CY (1) | CY1123552T1 (ja) |
DK (1) | DK2776065T3 (ja) |
ES (1) | ES2859323T3 (ja) |
HK (1) | HK1201453A1 (ja) |
HR (1) | HRP20201370T1 (ja) |
HU (1) | HUE050985T2 (ja) |
LT (1) | LT2776065T (ja) |
MX (1) | MX2014005566A (ja) |
PL (1) | PL2776065T3 (ja) |
PT (1) | PT2776065T (ja) |
RS (1) | RS60920B1 (ja) |
RU (1) | RU2687588C2 (ja) |
SI (1) | SI2776065T1 (ja) |
WO (1) | WO2013070615A1 (ja) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102111171B1 (ko) | 2011-06-10 | 2020-05-14 | 메디뮨 엘엘씨 | 항슈도모나스 psl 결합 분자 및 그의 용도 |
KR102184343B1 (ko) | 2011-11-07 | 2020-11-30 | 메디뮨 엘엘씨 | 항슈도모나스 psl 및 pcrv 결합 분자를 이용한 병용 요법 |
AU2013224851B2 (en) * | 2012-03-02 | 2018-03-01 | Ablynx Nv | Pseudomonas aeruginosa PcrV binding single variable domain antibodies |
MX2015005719A (es) * | 2012-11-06 | 2016-01-12 | Medimmune Llc | Terapias de combinacion que usan moleculas de union anti-psl y pcrv de pseudomonas. |
US20160115250A1 (en) * | 2013-05-14 | 2016-04-28 | Medlmmune, Llc | Synthetic Oligosaccharide Subunits Of The PSL Exopolysaccharide Of Pseudomonas Aeruginosa And Uses Thereof |
EP3139950A4 (en) * | 2014-05-05 | 2017-12-20 | Medimmune, LLC | Multi-specific anti-pseudomonas psl and pcrv binding molecules and uses thereof |
TWI719938B (zh) * | 2014-06-19 | 2021-03-01 | 美商麥迪紐有限責任公司 | 多重細菌感染之治療 |
CN107922482A (zh) * | 2015-05-01 | 2018-04-17 | 英伊布里克斯有限合伙公司 | Iii型分泌系统靶向分子 |
KR20180042300A (ko) * | 2015-08-24 | 2018-04-25 | 메디뮨 엘엘씨 | Mrka 폴리펩티드, 항체 및 이의 용도 |
WO2017095744A1 (en) * | 2015-11-30 | 2017-06-08 | Medimmune, Llc | Method for preventing or treating nosocomial pneumonia |
EA201892525A1 (ru) * | 2016-05-05 | 2019-04-30 | Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания | Конструкции днк-антител для применения против pseudomonas aeruginosa |
KR20220019755A (ko) * | 2019-06-11 | 2022-02-17 | 리제너론 파마슈티칼스 인코포레이티드 | PcrV에 결합하는 항-PcrV 항체, 항-PcrV 항체를 포함하는 조성물, 및 이의 사용 방법 |
US20220289830A1 (en) * | 2019-07-09 | 2022-09-15 | Staidson (Beijing) Biopharmaceuticals Co., Ltd. | Antibodies specifically recognizing pseudomonas pcrv and uses thereof |
KR20210095781A (ko) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
WO2021244421A1 (en) * | 2020-06-01 | 2021-12-09 | Staidson (Beijing) Biopharmaceuticals Co., Ltd. | Antibodies specifically recognizing pseudomonas pcrv and uses thereof |
US20230295279A1 (en) * | 2020-08-07 | 2023-09-21 | Beijing Solobio Genetechnology Co., Ltd. | Antibodies Specifically Recognizing Pseudomonas Psl and Uses Thereof |
FR3114970B1 (fr) * | 2020-10-08 | 2023-06-30 | Univ Tours | Combinaison d’anticorps inhalés avec des agents immunomodulateurs pour le traitement ou la prévention d’inféctions respiratoires |
EP4247846A4 (en) * | 2020-11-18 | 2024-07-03 | Beijing Solobio Genetechnology Co Ltd | COMBINATIONS OF ANTIBODIES AND BISPECIFIC ANTIBODIES WITH ANTIGEN-BINDING SPECIFIC RECOGNITION OF PSEUDOMONAS PCRV AND PSL |
WO2023141611A2 (en) * | 2022-01-21 | 2023-07-27 | Lyvgen Biopharma Holdings Limited | Multi-specific antibodies in uses thereof in avidity receptor crosslinking and immune modulation |
WO2024003103A1 (en) | 2022-06-29 | 2024-01-04 | Astrazeneca Ab | Anti-pcrv and psl bispecific antibodies for treatment of bronchiectasis |
Family Cites Families (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
AU584690B2 (en) | 1985-03-11 | 1989-06-01 | Teijin Limited | E87ag antigen of pseudomonas aeruginosa, monoclonal antibody against it, and hybridoma |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5750373A (en) | 1990-12-03 | 1998-05-12 | Genentech, Inc. | Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
AU633698B2 (en) | 1990-01-12 | 1993-02-04 | Amgen Fremont Inc. | Generation of xenogeneic antibodies |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
US5525491A (en) | 1991-02-27 | 1996-06-11 | Creative Biomolecules, Inc. | Serine-rich peptide linkers |
JP3672306B2 (ja) | 1991-04-10 | 2005-07-20 | ザ スクリップス リサーチ インスティテュート | ファージミドを使用するヘテロ二量体受容体ライブラリー |
IE922437A1 (en) | 1991-07-25 | 1993-01-27 | Idec Pharma Corp | Recombinant antibodies for human therapy |
US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
US6130364A (en) | 1995-03-29 | 2000-10-10 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
JP2978435B2 (ja) | 1996-01-24 | 1999-11-15 | チッソ株式会社 | アクリロキシプロピルシランの製造方法 |
US6420140B1 (en) | 1996-10-11 | 2002-07-16 | Abgenix, Inc. | Production of multimeric protein by cell fusion method |
US6190370B1 (en) | 1997-07-25 | 2001-02-20 | Arrow International, Inc. | Devices, systems and methods for determining proper placement of epidural catheters |
NZ507381A (en) | 1998-04-21 | 2003-12-19 | Micromet Ag | CD19xCD3 specific polypeptides and uses thereof |
ES2379801T3 (es) | 1998-11-25 | 2012-05-03 | Mcw Research Foundation, Incorporated | Método para diagnosticar una infección por pseudomonas aeruginosa |
JP4368196B2 (ja) | 2000-11-17 | 2009-11-18 | ユニバーシティー オブ ロチェスター | 真核細胞において免疫グロブリン分子を製造および同定するインビトロにおける方法 |
ES2649037T3 (es) | 2000-12-12 | 2018-01-09 | Medimmune, Llc | Moléculas con semividas prolongadas, composiciones y usos de las mismas |
US7658921B2 (en) | 2000-12-12 | 2010-02-09 | Medimmune, Llc | Molecules with extended half-lives, compositions and uses thereof |
ATE347374T1 (de) * | 2001-01-26 | 2006-12-15 | Mcw Res Found Inc | Verfahren und zusammensetzungen für immunisierung mit dem pseudomonas antigen |
WO2002096948A2 (en) | 2001-01-29 | 2002-12-05 | Idec Pharmaceuticals Corporation | Engineered tetravalent antibodies and methods of use |
US20020146753A1 (en) * | 2001-04-06 | 2002-10-10 | Henrik Ditzel | Autoantibodies to glucose-6-phosphate isomerase and their participation in autoimmune disease |
US7119172B2 (en) | 2001-05-21 | 2006-10-10 | The Brigham And Women's Hospital, Inc. | P. aeruginosa mucoid exopolysaccharide specific binding peptides |
US20030232387A1 (en) * | 2002-06-14 | 2003-12-18 | Millennium Pharmaceuticals, Inc. | Antibodies that bind alphaE integrin |
US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
SG2014010029A (en) | 2005-08-19 | 2014-08-28 | Abbott Lab | Dual variable domain immunoglobin and uses thereof |
US20090215992A1 (en) | 2005-08-19 | 2009-08-27 | Chengbin Wu | Dual variable domain immunoglobulin and uses thereof |
US7790862B2 (en) | 2006-06-13 | 2010-09-07 | Zymogenetics, Inc. | IL-17 and IL-23 antagonists and methods of using the same |
JP2008133206A (ja) * | 2006-11-28 | 2008-06-12 | Yokohama City Univ | 緑膿菌に対して感染防御能を誘導できる医薬組成物 |
US7553936B2 (en) * | 2006-12-04 | 2009-06-30 | The United States of America as represented by Secretary Department of Health and Human Services | Anti-TREM-like transcript-1 (TLT-1) antibodies and compositions |
EP2102244A2 (en) | 2006-12-19 | 2009-09-23 | Ablynx N.V. | Amino acid sequences directed against a metalloproteinase from the adam family and polypeptides comprising the same for the treatment of adam-related diseases and disorders |
EP2220117A2 (en) * | 2007-11-30 | 2010-08-25 | Kalobios Pharmaceuticals, Inc. | Antibodies to the pcrv antigen of pseudomonas aeruginosa |
EP2248826B1 (en) * | 2008-01-10 | 2013-06-12 | Shionogi&Co., Ltd. | Antibody directed against pcrv |
ES2613963T3 (es) | 2008-01-18 | 2017-05-29 | Medimmune, Llc | Anticuerpos manipulados con cisteína para conjugación específica de sitio |
NZ592644A (en) | 2008-11-28 | 2013-09-27 | Abbott Lab | Stable antibody compositions and methods for stabilizing same |
JO3672B1 (ar) * | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
WO2010076326A1 (en) * | 2008-12-31 | 2010-07-08 | W. L. Gore & Associates Gmbh | Venting device |
EP2393515A1 (en) * | 2009-02-04 | 2011-12-14 | Kalobios Pharmaceuticals, Inc. | Combination antibiotic and antibody therapy for the treatment of pseudomonas aeruginosa infection |
BRPI1008977A2 (pt) * | 2009-03-11 | 2016-10-04 | Shionogi & Co | anticorpo para pcrv humanizado que possui atividade anti-pseudomonal |
US9096659B2 (en) * | 2009-03-18 | 2015-08-04 | Wake Forest University Health Sciences | Flagellin fusion proteins and use thereof to induce immune responses against Pseudomonas aeruginosa |
MX347291B (es) | 2009-03-20 | 2017-04-17 | Amgen Inc | Inmunoglobulinas portadoras y usos de las mismas. |
MX2011010634A (es) | 2009-04-09 | 2012-03-06 | Kenta Biotech Ag | Anticuerpos monoclonal humano especifico para lipopolisacaridos (lps) de serotipo iats 01 de pseudomonas aeruginosa. |
AU2010270979B2 (en) | 2009-06-22 | 2015-04-23 | Medimmune, Llc | Engineered Fc regions for site-specific conjugation |
JP2013515079A (ja) | 2009-12-22 | 2013-05-02 | カロバイオス ファーマシューティカルズ インコーポレイティッド | 低レベルの病原性シュードモナス・エルギノーサ(Pseudomonasaeruginosa)感染症を有する患者のスタフィロコッカス(Staphylococcus)感染症を治療する方法 |
EP2673373B3 (en) * | 2011-02-08 | 2021-06-02 | MedImmune, LLC | Antibodies that specifically bind staphylococcus aureus alpha toxin and methods of use |
WO2012145626A1 (en) | 2011-04-22 | 2012-10-26 | Ancora Pharmaceuticals Inc. | Synthetic oligosaccharides for staphylococcus vaccine |
KR102111171B1 (ko) | 2011-06-10 | 2020-05-14 | 메디뮨 엘엘씨 | 항슈도모나스 psl 결합 분자 및 그의 용도 |
EP2776061B1 (en) | 2011-11-07 | 2019-08-14 | MedImmune, LLC | Multispecific and multivalent binding proteins and uses thereof |
KR102184343B1 (ko) | 2011-11-07 | 2020-11-30 | 메디뮨 엘엘씨 | 항슈도모나스 psl 및 pcrv 결합 분자를 이용한 병용 요법 |
AU2013224851B2 (en) * | 2012-03-02 | 2018-03-01 | Ablynx Nv | Pseudomonas aeruginosa PcrV binding single variable domain antibodies |
KR102272744B1 (ko) | 2012-11-06 | 2021-07-06 | 메디뮨 엘엘씨 | 에스.아우레우스 연관 질병의 치료 방법 |
PL2917360T3 (pl) * | 2012-11-06 | 2020-06-29 | Medimmune, Llc | Przeciwciała dla determinant powierzchniowych S. aureus |
MX2015005719A (es) * | 2012-11-06 | 2016-01-12 | Medimmune Llc | Terapias de combinacion que usan moleculas de union anti-psl y pcrv de pseudomonas. |
US20160115250A1 (en) | 2013-05-14 | 2016-04-28 | Medlmmune, Llc | Synthetic Oligosaccharide Subunits Of The PSL Exopolysaccharide Of Pseudomonas Aeruginosa And Uses Thereof |
EP3139950A4 (en) * | 2014-05-05 | 2017-12-20 | Medimmune, LLC | Multi-specific anti-pseudomonas psl and pcrv binding molecules and uses thereof |
TWI719938B (zh) * | 2014-06-19 | 2021-03-01 | 美商麥迪紐有限責任公司 | 多重細菌感染之治療 |
WO2017095744A1 (en) * | 2015-11-30 | 2017-06-08 | Medimmune, Llc | Method for preventing or treating nosocomial pneumonia |
EA201892525A1 (ru) * | 2016-05-05 | 2019-04-30 | Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания | Конструкции днк-антител для применения против pseudomonas aeruginosa |
KR20220019755A (ko) * | 2019-06-11 | 2022-02-17 | 리제너론 파마슈티칼스 인코포레이티드 | PcrV에 결합하는 항-PcrV 항체, 항-PcrV 항체를 포함하는 조성물, 및 이의 사용 방법 |
-
2012
- 2012-11-06 KR KR1020147015274A patent/KR102184343B1/ko active IP Right Grant
- 2012-11-06 ES ES12847479T patent/ES2859323T3/es active Active
- 2012-11-06 US US14/356,500 patent/US10597439B2/en active Active
- 2012-11-06 LT LTEP12847479.8T patent/LT2776065T/lt unknown
- 2012-11-06 HU HUE12847479A patent/HUE050985T2/hu unknown
- 2012-11-06 AU AU2012336028A patent/AU2012336028A1/en not_active Abandoned
- 2012-11-06 RS RS20201211A patent/RS60920B1/sr unknown
- 2012-11-06 PL PL12847479T patent/PL2776065T3/pl unknown
- 2012-11-06 WO PCT/US2012/063722 patent/WO2013070615A1/en active Application Filing
- 2012-11-06 CA CA2854817A patent/CA2854817C/en active Active
- 2012-11-06 BR BR112014011028-0A patent/BR112014011028B1/pt active IP Right Grant
- 2012-11-06 RU RU2014122990A patent/RU2687588C2/ru active
- 2012-11-06 CN CN201280054651.8A patent/CN104136042B/zh active Active
- 2012-11-06 PT PT128474798T patent/PT2776065T/pt unknown
- 2012-11-06 MX MX2014005566A patent/MX2014005566A/es active IP Right Grant
- 2012-11-06 DK DK12847479.8T patent/DK2776065T3/da active
- 2012-11-06 SI SI201231834T patent/SI2776065T1/sl unknown
- 2012-11-06 JP JP2014540196A patent/JP6182152B2/ja active Active
- 2012-11-06 CA CA3161431A patent/CA3161431A1/en active Pending
- 2012-11-06 EP EP12847479.8A patent/EP2776065B1/en active Active
-
2015
- 2015-02-27 HK HK15101962.5A patent/HK1201453A1/xx unknown
-
2017
- 2017-08-25 AU AU2017219081A patent/AU2017219081B9/en active Active
-
2019
- 2019-09-05 AU AU2019226205A patent/AU2019226205A1/en not_active Abandoned
-
2020
- 2020-02-13 US US16/789,790 patent/US11203633B2/en active Active
- 2020-08-28 HR HRP20201370TT patent/HRP20201370T1/hr unknown
- 2020-10-08 CY CY20201100949T patent/CY1123552T1/el unknown
-
2021
- 2021-11-15 US US17/454,837 patent/US20220177554A1/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2015504421A5 (ja) | ||
RU2014122990A (ru) | Способы комбинированной терапии с применением молекул, связывающихся с psl и pcrv pseudomonas | |
JP2012525829A5 (ja) | ||
JP2013198490A5 (ja) | ||
JP2009225799A5 (ja) | ||
RU2017128882A (ru) | Антитела к биотину и способы их применения | |
RU2016100892A (ru) | Антитела против tweakr и их применение | |
JP2017523786A5 (ja) | ||
EA201190132A1 (ru) | Гуманизированные антитела, связывающиеся с cd19, и их применение | |
JP2018516853A5 (ja) | ||
JP2017149720A5 (ja) | ||
AU2016204274A1 (en) | Antibodies that bind to OX40 and their uses | |
HRP20221083T1 (hr) | Kombinirana terapija bispecifičnom antigen vezujućom molekulom koja aktivira t stanice i antagonistom vezivanja osi pd-1 | |
JP2014205674A5 (ja) | ||
ES2776179T3 (es) | Anticuerpos dirigidos contra determinantes de la superficie de S. aureus | |
JP2013506428A5 (ja) | ||
RU2018102606A (ru) | Молекулы, связывающиеся с psl pseudomonas, и пути их применения | |
JP2012530487A5 (ja) | ||
JP2009518005A5 (ja) | ||
RU2017134495A (ru) | Антитела к альфа-рецептору собачьего интерлейкина-4 | |
JP2020513791A5 (ja) | ||
RU2531523C3 (ru) | Стабильные и растворимые антитела, ингибирующие vegf | |
JP2016530223A5 (ja) | ||
JP2011517447A5 (ja) | ||
RU2016137110A (ru) | Антитела к компоненту комплемента с5 |